Search Results - "Armstrong, April W"

An update on psoriasis and metabolic syndrome: A meta-analysis of observational studies by Singh, Sanminder, Young, Paulina, Armstrong, April W

“…The relationship between psoriasis and metabolic syndrome is not well understood. Though multiple epidemiologic studies have suggested a link between psoriasis…”
Get full text

Psoriasis prevalence among adults in the United States by Rachakonda, Tara D., MD, MS, Schupp, Clayton W., PhD, Armstrong, April W., MD, MPH

“…Background Psoriasis is a chronic inflammatory disorder associated with significant morbidity and mortality. Up-to-date prevalence data on psoriasis provide…”
Get full text

Corticosteroids and wound healing: clinical considerations in the perioperative period by Wang, Audrey S., M.D, Armstrong, Ehrin J., M.D., M.Sc, Armstrong, April W., M.D., M.P.H

“…Abstract Background Determining whether systemic corticosteroids impair wound healing is a clinically relevant topic that has important management…”
Get full text

Psoriasis and metabolic syndrome: A systematic review and meta-analysis of observational studies by Armstrong, April W., MD, MPH, Harskamp, Caitlin T., BA, Armstrong, Ehrin J., MD, MSc

“…Background Increasing population-based studies have suggested a relationship between psoriasis and metabolic syndrome. Objective The objective of this study…”
Get full text

Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003-2011 by Armstrong, April W, Schupp, Clayton, Wu, Julie, Bebo, Bruce

“…To ascertain impairment in quality of life and work productivity among patients with psoriasis and psoriatic arthritis. From 2003 through 2011, the National…”
Get full text

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial by Reich, Kristian, MD, Armstrong, April W., MD, MPH, Foley, Peter, MD, Song, Michael, MD, Wasfi, Yasmine, MD, PhD, Randazzo, Bruce, MD, PhD, Li, Shu, PhD, Shen, Y.-K., PhD, Gordon, Kenneth B., MD

“…Background Phase II data suggested that guselkumab, an anti-interleukin-23 monoclonal antibody, was efficacious in psoriasis. Objective We sought to assess…”
Get full text

Treatment preferences and treatment satisfaction among psoriasis patients: a systematic review by Florek, Aleksandra G., Wang, Catherine J., Armstrong, April W.

“…A critical gap exists in determining treatment preferences and treatment satisfaction from patient perspectives, which is paramount to achieving therapeutic…”
Get full text

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis by Coates, Laura C., Kavanaugh, Arthur, Mease, Philip J., Soriano, Enrique R., Laura Acosta‐Felquer, Maria, Armstrong, April W., Bautista‐Molano, Wilson, Boehncke, Wolf‐Henning, Campbell, Willemina, Cauli, Alberto, Espinoza, Luis R., FitzGerald, Oliver, Gladman, Dafna D., Gottlieb, Alice, Helliwell, Philip S., Husni, M. Elaine, Love, Thorvardur J., Lubrano, Ennio, McHugh, Neil, Nash, Peter, Ogdie, Alexis, Orbai, Ana‐Maria, Parkinson, Andrew, O'Sullivan, Denis, Rosen, Cheryl F., Schwartzman, Sergio, Siegel, Evan L., Toloza, Sergio, Tuong, William, Ritchlin, Christopher T.

“…Objective To update the 2009 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) treatment recommendations for the spectrum of…”
Get full text

Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies by Armstrong, Ehrin J, Harskamp, Caitlin T, Armstrong, April W

“…Psoriasis is a chronic inflammatory disease that may be associated with increased risk of cardiovascular events, including cardiovascular mortality, myocardial…”
Get full text

Chronic spontaneous urticaria: Focus on pathophysiology to unlock treatment advances by Kaplan, Allen, Lebwohl, Mark, Giménez‐Arnau, Ana M., Hide, Michihiro, Armstrong, April W., Maurer, Marcus

“…Chronic spontaneous urticaria (CSU) is a debilitating skin disease characterized by intensely itchy wheals, angioedema, or both. Symptoms recur spontaneously,…”
Get full text

US Perspectives in the Management of Psoriasis and Psoriatic Arthritis: Patient and Physician Results from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey by Lebwohl, Mark G., Kavanaugh, Arthur, Armstrong, April W., Van Voorhees, Abby S.

“…Background The Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP), a population-based survey of patients, dermatologists, and…”
Get full text

JAK Inhibitors: Treatment Efficacy and Safety Profile in Patients with Psoriasis by Hsu, Leeyen, Armstrong, April W.

“…Janus kinase (JAK) pathways are key mediators in the immunopathogenesis of psoriasis. Psoriasis treatment has evolved with the advent of targeted therapies,…”
Get full text

Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa by Kimball, Alexa B, Okun, Martin M, Williams, David A, Gottlieb, Alice B, Papp, Kim A, Zouboulis, Christos C, Armstrong, April W, Kerdel, Francisco, Gold, Michael H, Forman, Seth B, Korman, Neil J, Giamarellos-Bourboulis, Evangelos J, Crowley, Jeffrey J, Lynde, Charles, Reguiai, Ziad, Prens, Errol-Prospero, Alwawi, Eihab, Mostafa, Nael M, Pinsky, Brett, Sundaram, Murali, Gu, Yihua, Carlson, Dawn M, Jemec, Gregor B.E

“…Hidradenitis suppurativa is a painful, chronic inflammatory skin disease. In two double-blind, placebo-controlled trials, treatment with adalimumab resulted in…”
Get full text

Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis by Lebwohl, Mark G, Stein Gold, Linda, Strober, Bruce, Papp, Kim A, Armstrong, April W, Bagel, Jerry, Kircik, Leon, Ehst, Benjamin, Hong, H. Chih-ho, Soung, Jennifer, Fromowitz, Jeff, Guenthner, Scott, Piscitelli, Stephen C, Rubenstein, David S, Brown, Philip M, Tallman, Anna M, Bissonnette, Robert

“…In two identical trials of treatment for psoriasis with the topical aryl hydrocarbon receptor–modulating agent tapinarof, clearance or near-clearance of…”
Get full text

Off-label biologic regimens in psoriasis: a systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapy by Brezinski, Elizabeth A, Armstrong, April W

“…While off-label dosing of biologic treatments may be necessary in selected psoriasis patients, no systematic review exists to date that synthesizes the…”
Get full text

One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: Results from the PSOARING 3 trial by Strober, Bruce, Stein Gold, Linda, Bissonnette, Robert, Armstrong, April W., Kircik, Leon, Tyring, Stephen K., Piscitelli, Stephen C., Brown, Philip M., Rubenstein, David S., Tallman, Anna M., Lebwohl, Mark G.

“…Tapinarof cream 1% once daily, an aryl hydrocarbon receptor-modulating agent, was significantly more efficacious than vehicle and well tolerated in two 12-week…”
Get full text

Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients by Menter, Alan, Cordoro, Kelly M., Davis, Dawn M.R., Kroshinsky, Daniela, Paller, Amy S., Armstrong, April W., Connor, Cody, Elewski, Boni E., Gelfand, Joel M., Gordon, Kenneth B., Gottlieb, Alice B., Kaplan, Daniel H., Kavanaugh, Arthur, Kiselica, Matthew, Kivelevitch, Dario, Korman, Neil J., Lebwohl, Mark, Leonardi, Craig L., Lichten, Jason, Lim, Henry W., Mehta, Nehal N., Parra, Sylvia L., Pathy, Arun L., Farley Prater, Elizabeth A., Rupani, Reena N., Siegel, Michael, Stoff, Benjamin, Strober, Bruce E., Wong, Emily B., Wu, Jashin J., Hariharan, Vidhya, Elmets, Craig A.

“…Psoriasis is a chronic, multisystem, inflammatory disease that affects approximately 1% of children, with onset most common during adolescence. This guideline…”
Get full text

National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2—Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments by Gelfand, Joel M., Armstrong, April W., Bell, Stacie, Anesi, George L., Blauvelt, Andrew, Calabrese, Cassandra, Dommasch, Erica D., Feldman, Steven R., Gladman, Dafna, Kircik, Leon, Lebwohl, Mark, Lo Re, Vincent, Martin, George, Merola, Joseph F., Scher, Jose U., Schwartzman, Sergio, Treat, James R., Van Voorhees, Abby S., Ellebrecht, Christoph T., Fenner, Justine, Ocon, Anthony, Syed, Maha N., Weinstein, Erica J., Gondo, George, Heydon, Sue, Koons, Samantha, Ritchlin, Christopher T.

“…To update guidance regarding the management of psoriatic disease during the COVID-19 pandemic. The task force (TF) includes 18 physician voting members with…”
Get full text

A Randomized Placebo-Controlled Trial of Secukinumab on Aortic Vascular Inflammation in Moderate-to-Severe Plaque Psoriasis (VIP-S) by Gelfand, Joel M., Shin, Daniel B., Duffin, Kristina Callis, Armstrong, April W., Blauvelt, Andrew, Tyring, Stephen K., Menter, Alan, Gottlieb, Scott, Lockshin, Benjamin N., Simpson, Eric L., Kianifard, Farid, Sarkar, Rajendra Prasad, Muscianisi, Elisa, Steadman, Jennifer, Ahlman, Mark A., Playford, Martin P., Joshi, Aditya A., Dey, Amit K., Werner, Thomas J., Alavi, Abass, Mehta, Nehal N.

“…Psoriasis, a chronic immune-mediated disease, is associated with an increased risk of cardiovascular events and mortality. Secukinumab selectively neutralizes…”
Get full text

Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review by Armstrong, April W, Read, Charlotte

“…IMPORTANCE: Approximately 125 million people worldwide have psoriasis. Patients with psoriasis experience substantial morbidity and increased rates of…”
Get full text